For those who would rather take their meds orally rather than injectable, this provides convenience and enhances treatment compliance
2.0 The Glucagon Paradox Before Retatrutide, the glucagon receptor had a twenty-year reputation for killing drug programs
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost ~28.7% of body weight (~71 lbs at 68 weeks) and saw substantial improvements in pain and function: WOMAC pain scores reduced by 4.5 points (75.8%) Meaningful gains in physical function, with many patients essentially free of knee pain by study end If these results are confirmed in broader use, were not just talking about weight loss drugs anymorewere talking about disease-modifying therapies that simultaneously target obesity, pain, mobility, and downstream CV risk
Third, build the foundation that makes any intervention work better
When it comes to losing weight, its important to have realistic goals
Abstract Glucagon-like petide-1 (GLP-1) potentiates insulin and suppresses glucagon secretion from the pancreas in response to the ingestion of nutrients
